In conclusion, we found that the pharmacological management of osteoporosis in women of 50 and over in this population combines an important overuse and, to a lesser extent, underuse, although the level of inappropriateness varied … Leer más
We identified a low-frequency non-coding variant near a novel locus, EN1, with an effect size fourfold larger than the mean of previously reported common variants for lumbar spine BMD (rs11692564) which was also associated with … Leer más
J Bone Miner Res. 2015 Oct;30(10):1747-53. doi: 10.1002/jbmr.2531. A position paper of the National Bone Health Alliance recently recommended that diagnostic criteria for osteoporosis be redefined. We review the merits and demerits of this proposal … Leer más
J Bone Miner Res. 2015 Oct;30(10):1758-66. doi: 10.1002/jbmr.2515. Epub 2015 May 10. In summary, for older men and women, calcium intakes of up to 1348 (316) mg/d from food were associated with decreased risks for … Leer más
Osteoporos Int. 2015 Oct 28. [Epub ahead of print] Osteoporosis treatments are usually given for a limited period of time in order to balance benefits and risks. We report three cases of postmenopausal women without … Leer más
Sclerostin and estradiol levels are associated with the response to bisphosphonate therapy in women with postmenopausal osteoporosis.
Curr Osteoporos Rep. 2015 Oct;13(5):287-301. doi: 10.1007/s11914-015-0282-z. Among women 50-64 years old, a Fracture Risk Assessment Tool (FRAX) threshold ≥9.3 % had a sensitivity of 33 % for identifying BMD T-score ≤-2.5 and 26 % … Leer más
The application of the NOGG and NOF guidelines led to a decrease in BMD indications, reducing costs and improving efficiency in the diagnostic management of osteoporosis, although variability exists between the guidelines.
Bone. 2015 Oct 20;83:35-47. doi: 10.1016/j.bone.2015.10.008. [Epub ahead of print] CONCLUSIONS: Our data not only confirm that AHSG is produced in bone, mainly in osteocytes, but show for the first time that its production is … Leer más
A986S polymorphism of CaSR is an independent predictor of PTH level in normocalcemic hyperparathyroidism patients, but not in asymptomatic hyperparathyroidism.
